cyrilzakka/clinical-trials huggingface dataset:
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer

The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven epithelial ovarian cancer
* Previously received no more than 4 cycles of neoadjuvant platinum based chemotherapy, followed by debulking surgery
* ECOG PFS \<_ 2
* Adequate haematological (absolute neutrophil count \>_ 1,500/mm3; platelets \>_ 100,000/mm3; hemoglobin \>_ 100g/L); renal (\<_ upper limit of normal) and hepatic function
* Age \>_ 18 years
* Written informed consent and the ability of the patient to co-operate with treatment and follow up

Exclusion Criteria:

* Contraindication to platinum/Paclitaxel chemotherapy: prior anaphylaxis to Carboplatin/Paclitaxel, unresolved or excessive toxicity from neoadjuvant chemotherapy. Patients must not have suffered significant bone marrow suppression during prior treatment. The significance of previous treatment delay and/or dose modification is to be determined by the Principle Investigator on a patient-by-patient basis.
* Serious concomitant medical condition, which in the investigators opinion would not make the patient a good candidate for the clinical trial.
* Patients with a past or concomitant malignancy other than skin cancer (excluding melanoma)
* Patients known to be serologically positive for Hepatitis B, C or HIV
* History of congestive heart failure or unstable angina or those who had a myocardial infarction within the past 6 months. Patients who were not expected to tolerate the hemodynamic effects of the fluid administered as part of the IP protocol.
* Patients who have not received chemotherapy prior to surgery
* Greater than 6 weeks from time of surgery to commencement of IP chemotherapy
* Residual disease greater than 1 cm at time of surgery. Patients whom in the surgeon's opinion are candidates for such surgery may be consented preoperatively to allow intraoperative IP catheter insertion. If however the surgeon is not able to reduce the bulk of disease to less than or equal to 1 cm, patients will be removed from the study and an IP catheter SHOULD NOT be placed.
Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions

This study is a prospective, multi-center, randomized controlled study, which evaluates the effectiveness and safety of cold laser plaque ablation for lower limb arterial stenosis and occlusive lesions from intermittent claudication to chronic threatening limb ischemia.

This study is a prospective, multi-center, randomized controlled study. This study will be conducted at four centers and is expected to enroll 110 patients. And we will evaluate the effectiveness and safety of cold laser plaque ablation compared to excimer laser system for lower limb arterial stenosis and occlusive lesions.

Eligibility Criteria:
Inclusion Criteria:

General selection criteria

1. Age between 18 and 85, gender is not limited;
2. Patients with symptomatic lower extremity arteriosclerosis disease (LEAD), Rutherford grade 2 to 5;
3. The stenosis of lower extremity arteries is greater than 70% or occlusion;
4. The subject is able and willing to comply with all requirements, including 6-month follow-up and evaluation, voluntary participation and informed consent.

Intraoperative contrast inclusion criteria

1. The internal diameter of the reference vessel proximal to the target lesion is greater than 1.8mm;
2. The stenosis of target lesion is greater than 70%;

Exclusion Criteria:

1. The target lesion is located in the artificial vascular or autologous venous vascular bypass;
2. Endovascular or surgical procedure in the target limb performed less than or equal to 30 days prior to the index procedure OR Planned endovascular or surgical procedure 30 days after the index procedure;
3. Intent to use other atherectomy device in the same procedure;
4. Flow-limiting dissection within, proximal or distal to the target lesion;
5. Evidence or history of aneurysm in the target vessel， intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months;
6. Uncorrected coagulation abnormalities (platelet count ≤ 75\*109/ L or INR≥2.0), bleeding constitution, and history of heparin-induced thrombocytopenia (HIT);
7. Any thrombolytic therapy was performed within 2 weeks before surgery;
8. History of severe trauma, fracture, major surgery, or parenchymal organ biopsy within 2 weeks before surgery;
9. Known allergy to contrast agents or perioperative drugs;
10. Anticoagulation, antiplatelet or thrombolytic therapy is prohibited;
11. Pregnant or lactating women;
12. Subjects participating in other clinical trials of drugs or medical devices;
13. Other circumstances assessed by the investigator as inappropriate to participate in the trial.
Adherence to Guidelines for Antibiotic Use in Respiratory Infections at Hospitals

The purpose of this study is to test a strategy to improve the quality of antibiotic use in lower respiratory tract infections (LRTIs) at hospitals. Therefore, a multifaceted intervention strategy is compared to a control strategy and the effectiveness and feasibility of the intervention is assessed.

Improving processes of care in patients with hospital LRTI has been related to better patient outcome. Inappropriate use of antibiotics has contributed to the emergence and spread of drug-resistant micro organisms and increased treatment costs. International guidelines provide recommendations for the initial evaluation and management of LRTI, including advice on judicious antibiotic therapy. Nonetheless, studies have demonstrated a wide variability in adherence to these guidelines.

To implement key recommendations in clinical practice, various strategies have been used, with mixed results. Perhaps the most important aspect of choosing a potentially effective intervention is that the choice of intervention should be based upon assessment of potential barriers in the target group. Many intervention studies are flawed by failing to control for secular trends.

The investigators performed a cluster randomised controlled trial, to study the effect of a multifaceted intervention strategy on the quality of antibiotic use for LRTI. Their intervention was tailored to the areas most in need for improvement and took perceived barriers in the target group into consideration at the individual hospital level.

Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to a respiratory care or internal medicine ward with community-acquired pneumonia or acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD)

Exclusion Criteria:

* Recent (\< 30 days) admission for LRTI
* Patients with underlying immunodeficiency (HIV infection, neutropenia, treatment with immunomodulating drugs, active hematological malignancies, anatomical or functional asplenia and hypogammaglobulinemia)
* Patients already on treatment with antibiotics for another culture proven infection at the time of admission
* Patients from nursing homes
* Patients who had been transferred to another hospital or ICU and patients who had died within 24 hours of admission
* Patients with very poor prognosis (life expectancy \< 2 weeks on admission).
Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow

The purpose of this study is to confirm the safety and effectiveness of the Internal Joint Stabilizer - Elbow.


Eligibility Criteria:
Inclusion Criteria:

* The subject is \>21 years of age.
* The subject is considered a candidate for the Internal Joint Stabilizer -Elbow (IJS-E) under one of the following indications:

  * Subjects where either the elbow sublocates or dislocates after repairing the injured ligaments and/or bones
  * The elbow has been subluxated or dislocated for more than 10 days prior to surgery
  * The elbow subluxes or dislocates after surgical repair/reconstruction
* The subject has sufficient quantity or quality of bone. Specifically there is sufficient trochlea of the distal humerus and of sufficient quality that the axis pin of the IJS-E has a secure hold as judged by the surgeon intra-operatively. Also, the screws placed in the ulna must be judged by the surgeon to have sufficient hold.
* The subject or legal guardian has been informed of the nature of the study, agrees to its provisions, and has provided informed written consent.
* The subject is willing to be available for the appropriate follow-up for the duration of the study.

Exclusion Criteria:

* The subject has one of the following conditions:

  * Presents with limited elbow motion as opposed to instability (subjects where instability is created through surgical release for chronic limitation of movement, soft tissue release, removal of adhesions and heterotopic ossification and/or fascial interposition will be excluded).
  * Active infection, suspicion of colonization or quiescent infection
  * Bacteremia
  * Bone loss greater than 30% of the total articulation or involving an entire column of the distal humerus
  * The subject has less than 50% of the height of the coronoid remaining, based on lateral x-ray view
  * Osteoporosis to the degree that the screws that insert into the ulna loosen during implantation
  * Material sensitivity to titanium or cobalt chrome
* The subject has imminent, known issues related to life expectancy.
* The subject is unable and/or unwilling to cooperate with study procedures, a rehabilitative program, or required follow-up visits.
* The subject has a condition that may interfere with the outcome or impede healing.
* The subject, in the opinion of the Clinical Investigator, has an existing condition that indicates he/she is not a good candidate for the study.
* The subject is unable or unwilling to give informed consent and/or who has no responsible family member willing to give consent.
* The subject is transient and has no fixed address.
* The subject is a prisoner.
* The subject is \<21 years of age, or \>21 years of age but skeletally immature.
Levetiracetam in Post-Traumatic Stress Disorder

The purpose of this study is to evaluate the short-term efficacy and safety of levetiracetam in post-traumatic stress disorder (PTSD) and to evaluate continuation effects of levetiracetam in preventing PTSD relapse. The hypothesis is that levetiracetam will be safe and effective in preventing relapse of PTSD.

This is an investigator-initiated, single site study, consisting of two phases: 8 weeks of open label treatment with levetiracetam (500-2000 mg/day) in patients with PTSD, and in those who demonstrate at least minimal improvement, 12 weeks of randomized, double-blind treatment with either levetiracetam or matching placebo.

Eligibility Criteria:
Inclusion Criteria:

* ages 18-65
* primary diagnosis of PTSD based on DSM-IV criteria and assessed by the MINI International Neuropsychiatric Interview (MINI)
* Davidson Trauma Scale (DTS) score of at least 40 on screening
* ability to provide written informed consent

Exclusion Criteria:

* any primary DSM-IV Axis I disorder other than PTSD
* substance abuse during the last 6 months
* a clinically unstable medical condition or clinically significant laboratory abnormalities
* suicide risk or serious suicide attempt during the last year
* concurrent use of psychotropic medications including benzodiazepines, barbiturates, antiepileptic drugs, antidepressants, buspirone, dietary supplements or herbal or homeopathic remedies with psychotropic effects
* recent (within the last 3 months) initiation of cognitive behavioral therapy
* failure of a previous trial of levetiracetam at 2000 mg/day
* pregnancy or lactation
* women of childbearing potential who are unwilling to practice an acceptable method of contraception
Using Diode Laser in 2nd Stage of Implant.

Dental Implants that are teeth replacements usually place with two stages. In the second stage the implant fixture, (which is the body that inserted in the bone is exposed to place the artificial tooth), is exposed using surgical blade, however; an alternative method using diode laser may be used. This study aimed to compare the two methods in relation to pain anticipated by the patients and the need for local anesthesia usage.

Second-stage implant exposure involves removing soft tissue above the dental implant, as a part of the implant procedures to replace the missing teeth which can be done either by using diode laser or traditional method This study included fifteen patients, aged between 18 and 70 years old. Implant exposure was performed on 15 patients has at least two implants in two groups: group 1 with a diode laser at 940nm and group 2 with the traditional method performed either using a puncture, flap, or incision in 5 private clinics and one governmental run hospital in city of Baghdad/ Iraq.

Eligibility Criteria:
Inclusion Criteria:

- 1. Describe the target population and the criteria for their inclusion. Patients indicated for fixed implant treatment with conventional Implant procedure with implant insertd before (3-6) months by using two stage dental implant.

2. Treatment with two or more implant in same patient. 3. Patients aged from 18 to 70 years of both the gender with the presence of adequate osseointegration and healthy keratinized tissue surrounding the implant site.

Exclusion Criteria:

* 1. Patient have single implant. 2. Expose dental implant or already have gingival former. 3. Poor oral hygiene. 4. Failure implant osseointegration to bone.
Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings

The GENOME + project will enroll patients (n = ca. 100) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism. As well healthy parents of those affected for trio analysis (exception of one parent is not available for the study).

In the GENOME+ study (monocentric, prospective, open-label diagnostic study), patients with molecularly undiagnosed diseases will diagnostically be analyzed by means of omics technologies or re-analyzed using existing datasets. The following questions will be leading the study:

Primary:

• Identification of the molecular causes of unclear rare diseases

Secondary:

* Improve number of diagnoses for patients with rare diseases
* Further characterization of the identified putative disease causes
* Increase number of patients receiving appropriate therapy after successful diagnosis.

In addition, healthy parents of the subjects may be included in the study to perform parent-child (trio) analyses.

In addition, phenotype and omics data will be shared within the University Hospital Tübingen, Germany and with external collaborators to improve the diagnostic rate of the patients included in the study.

Storage of blood or tissue samples is not primary goal of this project, but may be necessary for further analyses.

Eligibility Criteria:
Inclusion Criteria:

* Unclear diagnosis
* Suspected genetic cause of the disease
* Previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism
* Healthy parents of those affected for trio analysis (exception of one parent is not available for the study)

Exclusion Criteria:

* Missing informed consent of the patient and her/his parents
Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial

The objective of this study is to determine if there is a significant difference in post-operative trichiasis at 12 months comparing a new procedure, the Bevel/rotate/advance procedure (BRAP), to the Trabut procedure among repeat surgery patients.

The investigators will randomize participants with previously operated trichiasis on a 1:1 basis to receive either the Bevel/rotate/advance procedure (BRAP) or the Trabut procedure. The participants will be followed at 1 day, 2 weeks, 3-6 months, and then 12 months following the surgery. The primary study endpoint is recurrence of post-operative trichiasis within 12 months of surgery. The investigators will conduct logistic regression analysis comparing post-operative trichiasis recurrent rates in participants receiving BRAP versus participants receiving Trabut. Adjusted analyses will account for demographic characteristics as well as trichiasis severity prior to surgery.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 or older
* At least one eyelid with post-operative upper eyelid trichiasis
* Willing to comply with all study procedures and be available for the duration of the study

Exclusion Criteria:

* Inability to provide independent, informed consent
Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar levels significantly in comparison with placebo, and observe if the reduced lung function could be recovered in patients with type 2 diabetes (T2DM) and chronic obstructive pulmonary disease (COPD) simultaneously.


Eligibility Criteria:
Inclusion Criteria:

* Subjects are between 50-85 years old, and clinical diagnosis of T2DM (HbA1c ≥ 6.5% or fasting plasma glucose ≥ 126 mg/dL or oral glucose tolerance test 2-hour plasma glucose ≥ 200 mg/dL).
* Patients with stable pulmonary obstruction (pulmonary function FEV1/FVC \<0.7) with symptoms of pulmonary obstruction.
* Subjects can cooperate with the collection of experimental specimens and return for regular visits.
* The patient or family members have signed the informed consent form.
* The patient must receive adjuvant treatment with probiotic for 12 weeks.

Exclusion Criteria:

* The patient or caregiver is unable to follow the physician's instructions for the trial, including the completed symptom assessment form and compliance with medication.
* The patient has a history of related allergic reactions, or the use of other highly sensitive or contraindicated drugs (Allergy to antibiotics or antipyretics).
* The patient have taken oral immunosuppressive drugs, intravenous steroids or T cell inhibitor ointments within the past 2 weeks.
* The patient has consumed probiotic-related products (including drops, lozenges, capsules, powder and yogurt) within the past 1 month.
* The patient received high doses of steroids within the past 1 month.
* The patient with active infection or severe pulmonary disease (eg, tuberculosis, bronchiectasis, or fibrosis).
* The patient is receiving treatment for a major disease or congenital disease.
* The patient is not suitable to participate in the trial as assessed by the professional physician.
A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Eligibility Criteria:
Inclusion Criteria:

* patients with chronic cancer pain
* between 20-80 years old age

Exclusion Criteria:

* the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal)
* psychiatric or neurologic disease
* unable to communicate verbally
* nausea and vomiting
* patient's refusal
A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

This study will evaluate safety, pharmacokinetics (PK), and the ability of MK-1075 to suppress viral load (VL) in HCV-infected participants during 7 days of once daily dose administration. The primary hypothesis is at a once-daily dose that is sufficiently safe and well tolerated in HCV-infected participants, the mean maximum HCV RNA (log10 IU/mL) reduction is at least 3 log10 IU/mL as compared to baseline following multiple dose oral administration of MK-1075 in HCV genotype 1 (GT1) and genotype 3 (GT3) infected participants.


Eligibility Criteria:
Inclusion Criteria:

* Female of non-childbearing potential
* Have a body mass index (BMI) \>=18 to =\< 37 kg/m\^2
* Excepting HCV infection, be in good health
* Have a clinical diagnosis of chronic HCV infection, exclusively GT1 or exclusively GT3
* Agree to follow smoking restrictions

Exclusion Criteria:

* Has a history of clinically significant, not stably controlled endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases.
* Have been treated with amiodarone within the prior year, or is currently on beta-blockers or verapamil
* Has a history of cancer (malignancy)
* Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
* Is positive for hepatitis B surface antigen or human immunodeficiency virus (HIV)
* Has had major surgery, donated or lost approximately 500 mL blood within 4 weeks prior to screening visit
* Has participated in another drug trial within 4 weeks prior to screening visit
* Is taking a non-permitted medication to treat a co-morbid condition
* Consumes greater than 2 glasses of alcoholic beverages
* Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 12 months
* Has evidence or history of chronic hepatitis not caused by HCV, including but not limited to non-HCV viral hepatitis, non-alcoholic steatohepatitis (NASH), drug-induced hepatitis, or autoimmune hepatitis
* Has been treated with other HCV inhibitors, such as sofosbuvir or VX-135
* Has evidence of advanced or decompensated liver disease, bridging fibrosis or higher grade fibrosis from a prior liver biopsy
Does the COVID-19 Vaccination Rate Change According to the Education, Income, Culture Level, Prosociality ?

"Does the COVID-19 vaccination rate change according to the education, income, culture level, social mindfulness and prosociality ?"

In this study the investigators will examine the correlation of the COVID-19 vaccination rates of the cities with income, cultural level and various education levels. Furthermore, vaccination rate change with respect to social mindfulness and prosociality will be investigated also? The investigators hypothesize that a) Income \& culture level is positively correlated with vaccination rate, b) If "time spent in education" increases (from illiterate, primary/mid/high school to BSc, MSc \& PhD) vaccination level increases, c) if social mindfullness or prosociality increases, vaccination rate increase also? The results of this study make it easier for us to understand why anti-vaccine people are against vaccination. The results may lead to more different variables and questions being included in questionnaires to understand resistance against vaccination.

Our basic variables are vaccination rates of cities, education level distribution (illiterate, primary school, middle school, high school, bachelor's degree, master degree, doctoral degree percentages) of cities, per capita income in the city, number of movie theaters per capita in the city and internet book sales of cities in Turkey. the investigators will do this work for other countries also as new data become available.

For social mindfulness and prosociality vs. vaccination rate investigation, the investigators will use primarily Doesum et al.'s 2021 research variables: SVO (Social value orientation) and SoMi (Social Mindfulness) with WHO vaccination rate tables.

Eligibility Criteria:
Inclusion Criteria:

* over 15 years old

Exclusion Criteria:

* under 15 years old